OBJECTIVE: The apolipoprotein E (APOE) ε4 allele enhances cerebral accumulation of β-amyloid (Aβ) and is a major risk factor for sporadic Alzheimer's disease. We hypothesized that HIV-associated neurocognitive disorders (HAND) would be associated with the APOE ε4 genotype and cerebral Aβ deposition. DESIGN: Clinicopathological study of HIV-infected adults from four prospective cohorts in the US National NeuroAIDS Tissue Consortium. METHODS: We used multivariable logistic regressions to model outcomes [Aβ plaques (immunohistochemistry) and HAND (standard criteria)] on predictors [APOE ε4 (allelic discrimination assay), older age (≥50 years), Aβ plaques, and their two-way interactions] and comorbid factors. RESULTS: Isocortical Aβ deposits generally occurred as diffuse plaques and mild-to-moderate amyloid angiopathy. Isocortical phospho-Tau-immunoreactive neurofibrillary lesions were sparse. The APOE ε4 and older age were independently associated with the presence of Aβ plaques [adjusted odds ratio (OR) 10.16 and 5.77, 95% confidence interval (CI) 2.89 - 35.76 and 1.91-17.48, P = 0.0003 and 0.0019, respectively, n = 96]. The probability of HAND was increased in the presence of Aβ plaques among APOE ε4 carriers (adjusted OR 30.00, 95% CI 1.41-638.63, P = 0.029, n = 15), but not in non-ε4 carriers (n = 57). CONCLUSION: The APOE ε4 and older age increased the likelihood of cerebral Aβ plaque deposition in HIV-infected adults. Generally, Aβ plaques in HIV brains were immunohistologically different from those in symptomatic Alzheimer's disease brains. Nonetheless, Aβ plaques were associated with HAND among APOE ε4 carriers. The detection of APOE ε4 genotype and cerebral Aβ deposition biomarkers may be useful in identifying living HAND patients who could benefit from Aβ-targeted therapies.
OBJECTIVE: The apolipoprotein E (APOE) ε4 allele enhances cerebral accumulation of β-amyloid (Aβ) and is a major risk factor for sporadic Alzheimer's disease. We hypothesized that HIV-associated neurocognitive disorders (HAND) would be associated with the APOE ε4 genotype and cerebral Aβ deposition. DESIGN: Clinicopathological study of HIV-infected adults from four prospective cohorts in the US National NeuroAIDS Tissue Consortium. METHODS: We used multivariable logistic regressions to model outcomes [Aβ plaques (immunohistochemistry) and HAND (standard criteria)] on predictors [APOE ε4 (allelic discrimination assay), older age (≥50 years), Aβ plaques, and their two-way interactions] and comorbid factors. RESULTS: Isocortical Aβ deposits generally occurred as diffuse plaques and mild-to-moderate amyloid angiopathy. Isocortical phospho-Tau-immunoreactive neurofibrillary lesions were sparse. The APOE ε4 and older age were independently associated with the presence of Aβ plaques [adjusted odds ratio (OR) 10.16 and 5.77, 95% confidence interval (CI) 2.89 - 35.76 and 1.91-17.48, P = 0.0003 and 0.0019, respectively, n = 96]. The probability of HAND was increased in the presence of Aβ plaques among APOE ε4 carriers (adjusted OR 30.00, 95% CI 1.41-638.63, P = 0.029, n = 15), but not in non-ε4 carriers (n = 57). CONCLUSION: The APOE ε4 and older age increased the likelihood of cerebral Aβ plaque deposition in HIV-infected adults. Generally, Aβ plaques in HIV brains were immunohistologically different from those in symptomatic Alzheimer's disease brains. Nonetheless, Aβ plaques were associated with HAND among APOE ε4 carriers. The detection of APOE ε4 genotype and cerebral Aβ deposition biomarkers may be useful in identifying living HAND patients who could benefit from Aβ-targeted therapies.
Authors: Joseph M Castellano; Jungsu Kim; Floy R Stewart; Hong Jiang; Ronald B DeMattos; Bruce W Patterson; Anne M Fagan; John C Morris; Kwasi G Mawuenyega; Carlos Cruchaga; Alison M Goate; Kelly R Bales; Steven M Paul; Randall J Bateman; David M Holtzman Journal: Sci Transl Med Date: 2011-06-29 Impact factor: 17.956
Authors: K Kantarci; V Lowe; S A Przybelski; S D Weigand; M L Senjem; R J Ivnik; G M Preboske; R Roberts; Y E Geda; B F Boeve; D S Knopman; R C Petersen; C R Jack Journal: Neurology Date: 2011-12-21 Impact factor: 9.910
Authors: John R Cirrito; Brianne M Disabato; Jessica L Restivo; Deborah K Verges; Whitney D Goebel; Anshul Sathyan; Davinder Hayreh; Gina D'Angelo; Tammie Benzinger; Hyejin Yoon; Jungsu Kim; John C Morris; Mark A Mintun; Yvette I Sheline Journal: Proc Natl Acad Sci U S A Date: 2011-08-22 Impact factor: 11.205
Authors: Virawudh Soontornniyomkij; Ian P Everall; David J Moore; Ben Gouaux; Erick T Tatro; Vadim Gospodarev; Eliezer Masliah; Nicole S Yin; Harry V Vinters; Cristian L Achim Journal: J Neurovirol Date: 2012-01-11 Impact factor: 2.643
Authors: Beau M Ances; Tammie L Benzinger; Jon J Christensen; Jewell Thomas; Rohit Venkat; Mengesha Teshome; Patricia Aldea; Anne M Fagan; David M Holtzman; John C Morris; David B Clifford Journal: Arch Neurol Date: 2012-01
Authors: Linda Chang; Caroline Jiang; Eric Cunningham; Steven Buchthal; Vanessa Douet; Marilou Andres; Thomas Ernst Journal: Neurology Date: 2014-05-21 Impact factor: 9.910
Authors: Virawudh Soontornniyomkij; Anya Umlauf; Sandra A Chung; Megan L Cochran; Benchawanna Soontornniyomkij; Ben Gouaux; Will Toperoff; David J Moore; Eliezer Masliah; Ronald J Ellis; Igor Grant; Cristian L Achim Journal: AIDS Date: 2014-06-01 Impact factor: 4.177